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Sir,
In response to the comments of Lemen et al (2013) on our
article (McCormack et al, 2012), we welcome the opportunity to
endorse the original article and to demonstrate that none of the
concerns raised are substantiated.
Our research was designed specifically to address the relation-
ship between mesothelioma and asbestos-related lung cancer
(ARLC) mortality, primarily in the form of a ARLC:mesothelioma
ratio. This point is critical to interpreting our design and results.
Lemen et al (2013) express concerns pertaining to four issues: (i)
studies included and omitted; (ii) a lack of consideration of further
factors that affect asbestos-related cancer risks; (iii) discussions of
the carcinogenicity of chrysotile; and (iv) risk mitigation. We
address each of these in turn.
Our study included 68 risk estimates drawn from 55 studies. To
estimate the ARLC:mesothelioma ratio, each study was required to
have examined both cancer outcomes during the same follow-up
period (see inclusion criteria). Thus, the recent update of the
Balangero cohort (Mirabelli et al, 2008) was intentionally omitted
having assessed only one of the two cancer end points. We are not
aware of any studies that were incorrectly omitted; all eligible
studies referenced by the two Hodgson and Darnton (2000, 2010)
articles were included, including the North Carolina cohort
(Loomis et al, 2009) that prompted the risk updates. It is not
appropriate to compare the studies we included to those included
in a meta-analysis with a completely different aim. In our analysis,
excess cancer deaths were calculated for each cohort based on
observed minus expected deaths, the latter based on national/
regional age- and sex-specific rates. Thus, neither the number of
excess deaths nor the ratio for each cohort, as a whole, is influenced
by the quality or even availability of exposure data. Hence, we had
no reasons to exclude the Quebec cohort (Liddell et al, 1997).
Our paper emphasises that the estimated fibre-specific ratios
‘characterise the overall ARLC–mesothelioma relationship across
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exposure circumstances and over a long period of time, and do not
serve to precisely quantify lung cancer excess in a short time
period.’ Such ratios are also the most relevant when applied
externally to estimate ARLCs from observed mesotheliomas, as the
latter usually arise from a combination of different, often
unknown, exposure histories. As pointed out by Lemen et al
(2013) and in the devoted Discussion section (‘Heterogeneity in
ratio estimates within and between cohorts’), variations in the
ARLC:mesothelioma ratios between cohorts or between subsets of
workers within cohorts may indeed occur due to outcome
misclassification, latency, exposure levels, potential confounding.
Nevertheless, the best estimates of the average ratios across
exposure circumstances are the ones we presented, being based on
the most complete evidence-base possible.
On the carcinogenicity of chrysotile, our article clearly
shows that there are both excesses of mesothelioma
(four mesothelioma deaths per 1000 deaths) and lung cancer
(SMR 1.7, table 3) associated with chrysotile. This is
entirely consistent with the IARC classification of chrysotile as a
Group 1 carcinogen to humans (IARC, 2012). At no point do we
conclude that ‘mesothelioma occurring in chrysotile-exposed
cohorts is due to other asbestos types’; rather we considered it
valid to discuss that when multiple carcinogenic fibres are present,
the relevant contribution of each is more difficult to disentangle.
This is particularly the case for chrysotile in the presence of
amphiboles because, as concluded by the most recent meeting of
the IARC Monographs, the latter appears to have a greater potency
for the induction of mesothelioma than does chrysotile (IARC,
2012).
Lemen et al (2013) misinterpret our paper suggesting that it
‘minimises the health risks posed by chrysotile’. On the contrary,
we concluded the paper by emphasising the cancer risks posed by
this asbestos fibre, risks that are often overlooked because they are
lung cancers typically occurring in smokers. Finally, on the
potential for the reduction of asbestos-related cancers, we focussed
on relevant actions in two exposure groups. In currently exposed
workers, removing exposure is a priority, which is consistent with
WHO’s position that the most efficient way to eliminate asbestos-
related diseases is to stop the use of all types of asbestos
(World Health Organization, 2010). Because this is not an option
for formerly exposed workers, we highlighted the benefits of
smoking cessation for this group. Unquestionably smoking
cessation has multiple benefits for all smokers, regardless of their
current or past asbestos exposure, and at no point do we suggest
otherwise.
We trust that the concerns of Lemen et al (2013) are sufficiently
addressed herein and that the important public health message of
the extent of both the mesothelioma and lung cancer burdens due
to all types of asbestos fibres is clear.
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